Dr. Peter Sguigna
Neurology (Neurology Physician)
5201 Harry Hines Blvd, Graduate Medical Education
Dallas, TX 75235
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 125
Licensed in Texas since 2018, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Texas Southwestern Medical School at Dallas
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TX license R7108 (first issued 2018; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 125
- Services billed
- 227
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Imaging of retina | 64 | 63 |
| Established patient office or other outpatient visit, 40-54 minutes | 42 | 35 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 19 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Dallas, TX | 54 |
| Dalfampridine Er (dalfampridine) | 33 |
| Modafinil Other prescribers in Dallas, TX | 21 |
| Baclofen Other prescribers in Dallas, TX | 17 |
| Zolpidem Tartrate Other prescribers in Dallas, TX | 17 |
| Glatiramer Acetate | 17 |
| Clonazepam Other prescribers in Dallas, TX | 17 |
| Nortriptyline Hcl Other prescribers in Dallas, TX | 14 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 14 |
| Actemra (tocilizumab) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 14 payments worth $16,755 in total to this clinician.
| EMD Serono, Inc. | $10,849 |
|---|---|
| Amgen Inc. | $5,906 |
| Consulting Fee | $15,375 |
|---|---|
| Food and Beverage | $680 |
| Travel and Lodging | $640 |
| Education | $60.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| EMD Serono, Inc. May 16, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $10,425 |
| Amgen Inc. Apr 15, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $4,950 |
| Amgen Inc. Apr 4, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to SAN DIEGO, CA · in-kind | $393 |
| EMD Serono, Inc. Mar 27, 2025 | Travel and Lodging travel to Nashville, TN Company’s descriptionSpeaking Services (Lodging) | $247 |
| Amgen Inc. Mar 17, 2025 | Education UPLIZNA · Inflammation/Rare Disease · in-kind | $60.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $77,627 in research payments for these studies, mostly to the institutions running them.
- Ocrelizumab PPMS High Dose Study
Genentech, Inc. - A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, F…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.